WO2003051979A2 - Compositions and methods for high sorption of skin materials and delivery of sulfur - Google Patents

Compositions and methods for high sorption of skin materials and delivery of sulfur Download PDF

Info

Publication number
WO2003051979A2
WO2003051979A2 PCT/US2002/039375 US0239375W WO03051979A2 WO 2003051979 A2 WO2003051979 A2 WO 2003051979A2 US 0239375 W US0239375 W US 0239375W WO 03051979 A2 WO03051979 A2 WO 03051979A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
sulfur
gum
swelling clay
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/039375
Other languages
English (en)
French (fr)
Other versions
WO2003051979A3 (en
Inventor
Jonah Shacknai
Eugene H. Gans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21809828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003051979(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2003552851A priority Critical patent/JP2005513070A/ja
Priority to EP02797252A priority patent/EP1467701A4/en
Priority to IL16239602A priority patent/IL162396A0/xx
Priority to BR0215053-0A priority patent/BR0215053A/pt
Priority to MXPA04006018A priority patent/MXPA04006018A/es
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Priority to CA002471260A priority patent/CA2471260A1/en
Priority to AU2002362118A priority patent/AU2002362118A1/en
Publication of WO2003051979A2 publication Critical patent/WO2003051979A2/en
Publication of WO2003051979A3 publication Critical patent/WO2003051979A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention relates to compositions and methods for absorbing the sebum, sweat, and other substances on skin and delivering sulfur can be delivered to the skin, including but not limited to the epidermis, dermis and stratum corneum.
  • Skin may become irritated and certain skin disorders may be exacerbated by materials which accumulate on the skin, including but not limited to sebum (the fatty secretion of the sebaceous glands), sweat, make-up, and dirt, as well as residue from cosmetics and pharmaceuticals applied to the skin (collectively "skin materials").
  • skin materials including but not limited to seborrhea, acne rosacea and acne vulgaris are treated with numerous solutions, lotions and creams.
  • the problem of skin irritants including but not limited to skin materials, persists even during and after use of these treatments.
  • This invention provides for sulfur delivery to the skin, including but not limited to stratum corneum, epidermis, and dermis, and its cutaneous absorption, while also absorbing cutaneous irritants (including but not limited to skin materials, such as components of sweat, sebum, moisture, epidermal metabolites, as well as residue from cosmetics and pharmaceuticals applied to the skin).
  • cutaneous irritants including but not limited to skin materials, such as components of sweat, sebum, moisture, epidermal metabolites, as well as residue from cosmetics and pharmaceuticals applied to the skin.
  • Sulfur is a chemically active element. In addition to its elemental form, sulfur forms many compounds.
  • Forms of sulfur suitable for use in the present invention are those forms of elemental sulfur that are known to be useful in dermatological compositions, including but not limited to, colloidal, coated, enrobed, entrapped, fumed, precipitated, washed, and sublimed sulfur, milk of sulfur, and flowers of sulfur.
  • the preferred form of elemental sulfur for use in the present invention is precipitated sulfur.
  • Sulfur derivatives refers to any composition that contains organic or inorganic sulfides, inorganic sulf ⁇ tes, organic or inorganic mercaptans, or any other than is being applied to the skin or hair of a user, including but not limited to cationic sulfur compounds, such as selenium sulf ⁇ de, potassium sulfide, poly-potassium sulfide, poly-calcium poly- sulfide, H 2 S, sulfuric acid, bisulfides, sulfur dioxide, thiols, organic salts, sodium sulfacetamide, or combinations thereof (most preferably sodium sulfacetamide).
  • cationic sulfur compounds such as selenium sulf ⁇ de, potassium sulfide, poly-potassium sulfide, poly-calcium poly- sulfide, H 2 S, sulfuric acid, bisulfides, sulfur dioxide, thiols, organic salts, sodium sulfacetamide, or combinations thereof (most preferably sodium
  • Inorganic sulfides suitable for use in connection with the present invention are those inorganic sulfides known to be useful in dermatological compositions and include, but are not limited to, selenium sulfide, sodium thiosulfate as well as those inorganic sulfides having the formula: RS, RSH, R S, RSSR, or RSSH, wherein R is an inorganic element that can bind ionically or covalently with sulfur.
  • Organic sulfides suitable for use in connection with the present invention are those organic sulfides known to be useful in dermatological compositions and include, but are not limited to, those organic sulfides having the formula: RS, R2S, RSH, R'SSR', or R'SSH, wherein R' is an organic compound and its salts that can bind ionically or covalently with sulfur.
  • Exemplary organic sulfides include, but are not limited to sodium thioglycolate (sodium mercaptoacetic acid), and gluathione.
  • Inorganic sulf ⁇ tes suitable for use in the present invention are those inorganic sulfites known to be useful in dermatological compositions, including but not limited to, sulfites and metabisulfites.
  • the carrier for active ingredients must be "dermatologically acceptable” in the sense of being compatible with the active ingredients and not injurious to the subject.
  • Carriers include those suitable for topical administration and may be prepared by methods known in the art.
  • Skin is defined to include the epidermis, dermis, stratum corneum or combinations thereof on a mammal, preferably human, cat or dog.
  • An embodiment of the present invention is a high sorption composition which comprises sulfur and one or more sulfur derivative, and one or more high sorption base.
  • a high sorption base comprises one or more non-swelling clay, one or more gum, one or more swelling clay, one or more silicon, or combinations thereof.
  • the high sorption base allows both the penetration of the sulfur and sulfur derivatives and delivery to the skin, and also absorbs skin irritants (or irritants), including but not limited to skin materials.
  • Sulfur may be delivered to the skin in a therapeutically effective manner either as elemental sulfur or as a sulfur derivative. Once delivered to the skin, the sulfur or sulfur derivative may act directly or may first be converted to another sulfur-containing chemical entity.
  • Clay materials are sorptive minerals characterized by low bulk density and layered lattice crystal structures. These minerals are derived from condensed forms of silicic acid, H SiO 4 , where each silicon atom is surrounded by four oxygen atoms inducing a tetrahedral structure. Chains or two-dimensional sheets are formed when the tetrahedral structures are linked together by the sharing of common oxygen atoms. Clay materials are composed of such silica tetrahedral sheets with a central alumina octahedral sheet.
  • the non-swelling clay preferably comprises Kaolin, a hydrated aluminum silicate with an approximate formula Al 2 O 8 •2SiO 2 »H 2 O, such as Nanclay.
  • Swelling clays are known to swell to a very large extent when the dry clay is contacted with water, and include, smectites for example montmorillonite, bentonite, clinoptilolite, vermiculite, magadite, smectite, laponite, and beidellite, preferably magnesium aluminum silicate, such as Neegu Ultra by R.T. Nanderbilt Company, Inc., ⁇ orwalk, Connecticut.
  • the gum comprises a natural gum, an artificial gum or a combination thereof, preferably xanthan gum which is a high molecular weight heteropolysaccharide gum produced by a pure-culture fermentation of a carbohydrate with Xanthomonas campestris, such as Keltrol CGF by Calgon Corporation, Pittsburgh, PA.
  • xanthan gum which is a high molecular weight heteropolysaccharide gum produced by a pure-culture fermentation of a carbohydrate with Xanthomonas campestris, such as Keltrol CGF by Calgon Corporation, Pittsburgh, PA.
  • Silicon means any composition that contains silica, colloidal silica, colloidal hydrated silica, precipitated silica, or silica gels, including but not limited to silicon dioxide.
  • Another embodiment includes a composition comprising water, xanthan gum, magnesium aluminum silicate, kaolin, silicon dioxide, sodium sulfacetamide, sodium thiosulfate, glyceryl stearate, PEG- 100 stearate, quillaia saponaria extract, benzyl alcohol, and sulfur.
  • a composition comprising water, xanthan gum, magnesium aluminum silicate, kaolin, silicon dioxide, sodium sulfacetamide, sodium thiosulfate, glyceryl stearate, PEG- 100 stearate, quillaia saponaria extract, benzyl alcohol, and sulfur.
  • One embodiment of the present invention is a composition
  • a composition comprising sulfur, one or more sulfur derivatives, such as sodium sulfacetamide, sulfites, mercaptans or combinations thereof (preferably sodium sulfacetamide), and a pharmaceutically acceptable carrier which comprises a high sorption base.
  • sulfur and sulfur derivatives may be converted on, within or both on and within the skin surface layers by skin materials, such as sebum, moisture and sweat components into sulfur derivatives.
  • skin materials such as sebum, moisture and sweat components into sulfur derivatives.
  • These sulfur derivatives may have antimicrobial, antifungal, antiparasitic or a mixture of benefits.
  • the composition absorbs the irritants such as skin materials.
  • a high sorption base comprises one or more non-swelling clays (including but not limited to kaolin), one or more swelling clays (including but not limited to montmorillonite clays, preferably magnesium aluminum silicate, bentonite, hectorite (such as Bentone® 38 which is dimethyldistearyl ammonium hectorite by Rheox, Inc., Hightstown, New Jersey, and which is a suspending agent/non-surfactant and a solvent/viscosity reducing agent, and surface reactive montmorillonite), (including but not limited to stearalkonium hectorites), one or more natural gums (including but not limited to xanthan gum, guar gum, gum arabic, carrageenan and alginates), one or more non-ionic surfactants (including but not limited to stearates, palmitostearates, glycerides, sorbitan esters, polyoxyethylene ethers, polyoxyethylene glycol esters,
  • One embodiment of the present invention comprises a method for absorbing irritants from the skin and delivering sulfur to the skin.
  • a composition of sulfur, one or more sulfur derivatives, such as sodium sulfacetamide, sulfites, mercaptans or combinations thereof (most preferably sodium sulfacetamide), and a high sorption base with a pH of from about 6.5 to about 8.1 is topically applied to the effected skin.
  • the high sorption base comprises non-swelling clay, gum, swelling clay, silicon or combinations thereof.
  • the non-swelling clay is present preferably at about 15-20%, more preferably at about 18.00% (all percents are weight percents).
  • the gum is present preferably at about 0.20-1.00%, more preferably at about 0.30%.
  • the swelling clay is present preferably at about 1.00-2.00%, more preferably at about 1.50%.
  • the silicon is present preferably at about 0.00-10.00%, more preferably at about 5.00%.
  • the composition is applied to the skin, absorbs irritants from the skin, and delivers sulfur to the skin.
  • the delivered sulfur may be from the sulfur, sulfur derivatives or a combination thereof.
  • Another embodiment includes a composition
  • a composition comprising water, xanthan gum, magnesium aluminum silicate, kaolin, silicon dioxide, sodium sulfacetamide, sodium thiosulfate, glyceryl stearate, PEG- 100 stearate, quillaia saponaria extract (such as Negetol® Bois de Panama which is a propylene glycol and water mixture or Quillaia Negetol® GR- 038 Hydro by Gattefosse S.A., Saint Priest Cedex, France), benzyl alcohol, and sulfur.
  • the . glyceryl stearate and PEG- 100 stearate (such as Lipomulse® 165 by Lipo Chemicals, Inc. Paterson, New Jersey) have emollient, emulsifying and surfactant qualities.
  • the high sorption base in this invention promotes absorption of irritants but does not inhibit the delivery of the active ingredient, sulfur derivatives, to the skin.
  • Another embodiment of the invention is a method for enhancing absorption of sulfur in skin.
  • a composition of sulfur, one or more sulfur derivatives, preferably sodium sulfacetamide, sulfites, mercaptans or combinations thereof (most preferably sodium sulfacetamide), and a high sorption base, with a pH of from about 6.5 to about 8.1 is topically applied to the effected skin.
  • the sulfur derivative is preferably present at about 10%-15% by weight.
  • the sulfur may be absorbed in the skin; and may be from the sulfur, sulfur derivatives or combinations thereof.
  • Another embodiment of the present invention is a method of delivering sulfur (from the sulfur, sulfur derivatives, or combinations thereof in the composition) to the skin and absorbing irritants including but not limited to skin materials from the facial skin of a human subject.
  • a composition of sulfur, one or more sulfur derivatives, preferably sodium sulfacetamide, sulfites, mercaptans or combinations thereof (most preferably sodium sulfacetamide), and a high sorption base with a pH of from about 6.5 to about 8.1 is topically applied to the effected skin.
  • the sulfur is preferably at about 5% and an additional sulfur derivative is preferably present at about 10%.
  • One embodiment of the present invention is the following preferred composition.
  • a composition according to the invention containing 5% (radiolabeled) sulfur in addition to sodium sulfacetamide was applied at real-life use levels to the surface of wetted excised human skin mounted in a skin penetration cell. After 12 hours, the skin was rinsed and wiped off, and a second dose was then applied for an additional 12 hours. Then, the radiolabeled sulfur was determined (a) on the surface of and within the stratum corneum; (b) within the epidermis and within the dermis; and (c) within the reservoir (the reservoir was designed to emulate the blood circulation below the skin) underneath the skin which represents the amount passing through the skin.
  • the present invention in another embodiment may be used to deliver sulfur below the dermis and epidermis and systemically as evidenced in the data regarding the reservoir.
  • radio-labeled sulfur S 35
  • S 35 radio-labeled sulfur
  • the following table displays the data in micrograms of sulfur delivered to the skin by the four high sorption formulations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2002/039375 2001-12-18 2002-12-10 Compositions and methods for high sorption of skin materials and delivery of sulfur Ceased WO2003051979A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2002362118A AU2002362118A1 (en) 2001-12-18 2002-12-10 Compositions and methods for high sorption of skin materials and delivery of sulfur
EP02797252A EP1467701A4 (en) 2001-12-18 2002-12-10 COMPOSITIONS AND METHODS FOR HIGH SORPTION OF SKIN MATERIALS AND ADDITION OF SULFUR
IL16239602A IL162396A0 (en) 2001-12-18 2002-12-10 A high sorption composition containing sulfur
BR0215053-0A BR0215053A (pt) 2001-12-18 2002-12-10 Composições e métodos de materiais de alta absorção de pele e liberação de enxofre
MXPA04006018A MXPA04006018A (es) 2001-12-18 2002-12-10 Composiciones y metodos para porcion elevada de materiales para la piel y suministro de azufre.
JP2003552851A JP2005513070A (ja) 2001-12-18 2002-12-10 高皮膚吸収および高硫黄送達のための組成物と方法
CA002471260A CA2471260A1 (en) 2001-12-18 2002-12-10 Compositions and methods for high sorption of skin materials and delivery of sulfur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/022,482 2001-12-18
US10/022,482 US6855342B2 (en) 2000-06-30 2001-12-18 Compositions and methods for high sorption of skin materials and delivery of sulfur

Publications (2)

Publication Number Publication Date
WO2003051979A2 true WO2003051979A2 (en) 2003-06-26
WO2003051979A3 WO2003051979A3 (en) 2004-01-22

Family

ID=21809828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039375 Ceased WO2003051979A2 (en) 2001-12-18 2002-12-10 Compositions and methods for high sorption of skin materials and delivery of sulfur

Country Status (10)

Country Link
US (3) US6855342B2 (https=)
EP (1) EP1467701A4 (https=)
JP (1) JP2005513070A (https=)
CN (1) CN1606430A (https=)
AU (1) AU2002362118A1 (https=)
BR (1) BR0215053A (https=)
CA (1) CA2471260A1 (https=)
IL (1) IL162396A0 (https=)
MX (1) MXPA04006018A (https=)
WO (1) WO2003051979A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422393B (zh) * 2004-12-22 2014-01-11 寶露化成工業股份有限公司 預防炎症之外用皮膚劑
FR3146804A1 (fr) * 2023-03-21 2024-09-27 L'oreal COMPOSITIONS ET PROCÉDÉS POUR éliminer la couleur des cheveux

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855342B2 (en) * 2000-06-30 2005-02-15 Medicis Pharmaceutical Corporation Compositions and methods for high sorption of skin materials and delivery of sulfur
US6977081B1 (en) 2002-12-18 2005-12-20 Upsher-Smith Laboratories, Inc. Facial cream composition containing allantoin
CN100353931C (zh) * 2003-06-23 2007-12-12 周彦忠 一种护肤洗浴用品及其应用
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
US20080145455A1 (en) * 2006-12-13 2008-06-19 Bedard Robert L Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents
WO2008116147A2 (en) 2007-03-21 2008-09-25 Colgate-Palmolive Company Structured compositions comprising a clay
WO2010079513A2 (en) * 2009-01-07 2010-07-15 Sanjay Banerji Painless treatment of warts, corns & callus
US9033907B2 (en) * 2009-03-30 2015-05-19 Aaron Matthew Noble Adjustable hinge
AU2010336460B2 (en) 2009-12-23 2013-06-13 Colgate-Palmolive Company Visually patterned and oriented compositions
CA2847264A1 (en) 2011-09-14 2013-03-21 Nuevas Alternativas Naturales, S.A.P.I. de C.V. Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
US12318406B2 (en) * 2013-03-15 2025-06-03 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US11318089B2 (en) 2013-03-15 2022-05-03 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US20220348517A1 (en) * 2021-04-28 2022-11-03 ArrMaz Products Inc. Novel chemistries to achieve a total agronomic coating containing micronutrients and/or biocatalysts

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634264A (en) 1967-11-02 1972-01-11 Univ California Method and composition for cleansing hair of animals
JPS55160721A (en) * 1979-06-02 1980-12-13 Tokyo Tanabe Co Ltd Pulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent
ATA910981A (de) 1981-06-12 1988-06-15 Rorer Int Overseas Verfahren zur herstellung kosmetischer und therapeutischer zusammensetzungen
RO87009B1 (ro) * 1983-05-09 1985-06-01 Octavian Plesa Sampon pentru par cu extracte de plante
US4587123A (en) 1984-06-28 1986-05-06 Price Jacqueline S Compositions and methods for reducing pest infestation
JPS61254525A (ja) * 1985-05-01 1986-11-12 Rooto Seiyaku Kk １１α−ヒドロキシプロゲステロンを配合したにきび治療剤
US4752472A (en) 1986-03-25 1988-06-21 Exovir, Inc. Cosmetic skin treatment useing cyanoacrylate polymer film
JPH032124A (ja) 1989-05-30 1991-01-08 Terumo Corp 外用液剤
ES2100239T3 (es) 1990-09-28 1997-06-16 Procter & Gamble Composiciones de champu mejoradas.
GB9213472D0 (en) 1992-06-25 1992-08-12 Unilever Plc Cosmetic composition
US5330980A (en) * 1992-08-25 1994-07-19 Shin Jae S Medicament for the topical treatment of skin
FR2697018B1 (fr) 1992-10-15 1994-12-09 Oreal Procédé de désodorisation d'un mercaptoacide et produit désodorisé ainsi obtenu.
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
GB9615631D0 (en) 1996-07-25 1996-09-04 Procter & Gamble Shampoo compositions
IT1291622B1 (it) 1997-04-18 1999-01-11 Marcello Izzo Uso dell'acido tioglicolico come agente depigmentante
EP1032355A1 (en) 1997-11-10 2000-09-06 The Procter & Gamble Company Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil
JP3605746B2 (ja) * 1998-02-12 2004-12-22 株式会社コーセー ニキビ用化粧料
US20020164381A1 (en) * 2000-06-30 2002-11-07 Medicis Pharmaceutical Corporation Mitocidal compositions and methods
US6855342B2 (en) * 2000-06-30 2005-02-15 Medicis Pharmaceutical Corporation Compositions and methods for high sorption of skin materials and delivery of sulfur
US6514489B1 (en) * 2000-06-30 2003-02-04 Medicis Pharmaceutical Corp. Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
US6429231B1 (en) 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422393B (zh) * 2004-12-22 2014-01-11 寶露化成工業股份有限公司 預防炎症之外用皮膚劑
US8741323B2 (en) 2004-12-22 2014-06-03 Pola Chemical Industries Inc. External skin agent comprising modified clay for preventing inflammation
FR3146804A1 (fr) * 2023-03-21 2024-09-27 L'oreal COMPOSITIONS ET PROCÉDÉS POUR éliminer la couleur des cheveux

Also Published As

Publication number Publication date
CA2471260A1 (en) 2003-06-26
US6855342B2 (en) 2005-02-15
JP2005513070A (ja) 2005-05-12
US6955825B2 (en) 2005-10-18
EP1467701A4 (en) 2006-10-11
BR0215053A (pt) 2004-11-23
WO2003051979A3 (en) 2004-01-22
AU2002362118A8 (en) 2003-06-30
CN1606430A (zh) 2005-04-13
US20020132015A1 (en) 2002-09-19
MXPA04006018A (es) 2005-03-31
EP1467701A2 (en) 2004-10-20
IL162396A0 (en) 2005-11-20
US20030161895A1 (en) 2003-08-28
US20040202729A1 (en) 2004-10-14
US6787160B2 (en) 2004-09-07
AU2002362118A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
US6855342B2 (en) Compositions and methods for high sorption of skin materials and delivery of sulfur
US4923900A (en) Therapeutic compositions containing benzoyl peroxide
US5086075A (en) Therapeutic compositions containing benzoyl peroxide
US5002974A (en) Anesthetic/skin moisturizing composition and method of preparing same
CA2943179C (en) Compositions and methods for enhancing the topical application of an acidic benefit agent
US5753637A (en) Method of treating acne conditions
JP5198846B2 (ja) 熱傷した皮膚のための方法及び組成物
MXPA04006023A (es) Composiciones acaricidas y metodos.
EP3074026B1 (en) Composition, system and method for treating skin
WO2015153074A1 (en) Compositions and methods for enhancing the topical application of a basic benefit agent
EP2323672A1 (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
US5916574A (en) Method of treating natural poison skin conditions
EP1685824A1 (en) Cosmetic composition
US6086924A (en) Skin care composition
HK1163555A (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
NZ721272B2 (en) Composition, system and method for treating skin
HU195616B (en) Process for producing mineral-based complex cosmetics and dermatological externals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 162396

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003552851

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/006018

Country of ref document: MX

Ref document number: 2471260

Country of ref document: CA

Ref document number: 20028255070

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002797252

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002797252

Country of ref document: EP